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Tissue plasminogen activator (tPA) and urokinase plasminogen acti-vator (uPA) differ in their modes of action. Efficient tPA-mediatedplasminogen activation requires binding to fibrin. In contrast, uPA
is fibrin independent and activates plasminogen in solution or when
associated with its cellular receptor urokinase protease activated receptor
(uPAR). We have previously shown that polyphosphate (polyP), alters
fibrin structure and attenuates tPA and plasminogen binding to fibrin,
thereby down-regulating fibrinolysis. Here we investigate the impact of
polyP on uPA-mediated fibrinolysis. As previously reported polyP of an
average chain length of 65 (polyP65) delays tPA-mediated fibrinolysis. The
rate of plasmin generation was also delayed and reduced 1.6-fold in
polyP65 -containing clots (0.74±0.06 vs. 1.17±0.14 pM/s in P<0.05).
Analysis of tPA-mediated fibrinolysis in real-time by confocal
microscopy was significantly slower in polyP65 -containing clots. In
marked contrast, polyP65 augmented the rate of uPA-mediated plasmin
generation 4.7-fold (3.96±0.34 vs. 0.84±0.08 pM/s; P<0.001) and acce-ler-
ated fibrinolysis (t1/2 64.5±1.7 min vs. 108.2±3.8 min; P<0.001). Analysis
of lysis in real-time confirmed that polyP65 enhanced uPA-mediated fibri-
no-lysis. Varying the plasminogen concentration (0.125-1 mM) in clots
dose-dependently enhanced uPA-mediated fibrinolysis, while negligible
changes were observed on tPA-mediated fibrinolysis. The accelerating
effect of polyP65 on uPA-mediated fibrinolysis was overcome by addition-
al plasminogen, while the down-regulation of tPA-mediated lysis and
plasmin generation was largely unaffected. polyP65 exerts opposing effects
on tPA- and uPA-mediated fibrinolysis, attenuating the fibrin cofactor
function in tPA-media-ted plasminogen activation. In contrast, polyP
may facilitate the interaction between fibrin-independent uPA and plas-
minogen thereby accelerating plasmin generation and downstream fibri-
nolysis. 
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ABSTRACT
Introduction
Polyphosphate (polyP) is a biomolecule composed of orthophosphate residues
(Pi) linked by phosphoanhydride bonds.1 polyP of average chain length of 
60-100-mers is a constituent of platelet dense granules and is released following
stimulation of platelets with different agonists.1,2 polyP acts at numerous points in
the coagulation cascade to augment clot formation, including stimulating factor XII
(FXII) activation, thrombin-mediated factor XI  (FXI) activation and interfering with
the function of TFPI.3 Our work has shown that polyP interferes with fibrin poly-
merization by stunting protofibril growth, producing a heterogeneous network of
dense ‘knotted’ regions interspersed by pores with altered mechanical properties.4
Plasmin is the serine protease responsible for degradation of fibrin. Two forms of
the zymogen precursor plasminogen circulate in plasma, the native more abundant
form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by
cleavage of the N-terminal peptide from Glu-plasminogen.5 Lys-plasminogen exists
in flexible open conformation, with an approximately 10-fold higher binding affi-
nity for plasminogen activators thereby facilitating its activation.6-9 Two-chain plas-
min is formed by enzymatic cleavage of plasminogen at Arg561-Val562.5,10 The two
main physiological plasminogen activators are the serine
proteases tissue plasminogen activator (tPA) and uroki-
nase plasminogen activator (uPA). Efficient plasminogen
activation by tPA requires fibrin as a cofactor, acting as a
template for its own dissolution by binding tPA and plas-
minogen.11 uPA is fibrin-independent and efficiently acti-
vates plasminogen in solution, but is often found in asso-
ciation with its cellular receptor, urokinase protease acti-
vated receptor (uPAR).12 uPAR does not have a catalytic
role but acts to localize plasminogen and uPA to the cell
surface increasing local reactant concentration.
We have previously shown that binding of tPA and plas-
minogen to fibrin is downregulated by polyP, in turn,
delaying tPA-mediated fibrinolysis.4 Here, we characterize
the impact of polyP on uPA-mediated plasminogen activa-
tion. Our data reveal that polyP has a strong accelerating
effect on uPA-mediated plasminogen activation that is
highly dependent on concentration of polyP and plas-
minogen. Enhanced uPA-mediated plasminogen activa-
tion in the presence of polyP translates as a robust profib-
rinolytic effect in clot lysis assays. These data exemplify
the complexity of polyP’s action on hemostasis and illus-
trate that the presence of different activators and sub-
strates in the local milieu can direct functional activity.   
Methods
Additional experimental details can be found in the Online
Supplementary Appendix.  
Ethical Consent
Ethical approval was obtained from the University of Aberdeen
College Ethics Review Board. 
Materials
PolyP70 was a kind gift from Dr Thomas Staffel BK Giulini GmbH
(Ludwigshafen, Germany).  PolyP 14, 60, 130 were a kind gift from
Dr Toshikazu Shiba Regenetiss Inc. Medium chain (p100) polyP
with and without biotin-labeling was from Kerafast Inc (Boston,
MA, USA). PolyP concentrations are expressed as monomer con-
centrations throughout (monomer formula NaPO3). All reactions
were carried out in TBST (50 mM Tris, 100 mM NaCl, 0.01%
Tween-20, pH 7.4).
Plasmin generation and uPA activity
Purified human plasminogen-free fibrinogen (2.4 mM), Glu- or
Lys-plasminogen (0–1 mM), tPA (20 pM) or uPA (180 pM) ± polyP65
(328 mM) in TBST was added in triplicate to 96-well polystyrene
plates. Clotting was initiated by thrombin (0.25 U/mL) and CaCl2
(5 mM), and activity quantified using the fluorogenic substrate D-
Val-Leu-Lys 7-amido-4-methylcoumarin (D–VLK-AMC [0.35
mM]) by measuring fluorescence release (excitation 360/40 nm,
emission 460/40 nm) every minute (min) for 5 hours (h) in a Biotek
Flx800 fluorescence microplate reader at 37 °C. The rate of plas-
min generation was calculated using; Longstaff C, 2016, Shiny
App for calculating zymogen activation rates, version 0.6
(https://drclongstaff.shinyapps.io/zymogenactnCL/). 
UPA activity was determined by incubating the enzyme (180
pM) ±328 mM polyP65 with the chromogenic substrate CS-61 44
(1.25 mM). Change in absorbance was measured every 30 seconds
(s) at 405 nm for 200 min.
Protein binding assays to biotin-labelled polyP
Binding of tPA, uPA, plasmin, FXII and activated FXII (FXIIa) to
biotin-labelled polyP (71 mM) were performed using an adaptation
of the protocol described by Choi et al.13 Bound tPA, uPA or plas-
min was detected with chromogenic substrates (1.2 mM S2288,
CS-61 44, or 0.6 mM S2251, respectively). FXII(a) was detected
using a peroxidase conjugated goat anti-human FXII antibody.  
Turbidimetric fibrinolysis assays
Purified human plasminogen-free fibrinogen (2.4 mM), Glu- or
Lys-plasminogen (0–1 mM), tPA (20 pM) or uPA (180 pM) with or
without polyP (0–1.3 mM) in TBST was added in triplicate to 96-
well polystyrene plates. Clotting was initiated by thrombin (0.25
U/mL) and CaCl2 (5 mM), and turbidity monitored every min at
340 nm for 5 h at 37°C in a FLX-800 plate reader (Biotek
Instruments).
Confocal Microscopy
Clots were prepared with human plasminogen-free fibrinogen
(2.65 mM) of which 9% was DyLight 488-labeled, Glu-plasmino-
gen (1.25 mM) of which 20% was DyLight 633-labeled, ±328 mM
polyP65 in TBST in Ibidi -slides VI0.4. Thrombin (0.25 U/mL) and
CaCl2 (5 mM) were added and fibrinolysis initiated by addition of
tPA or uPA (75 nM).  
Cascade blue ethylenediamine (CB)-labeled polyP70 was pre-
pared as described.13 Clots were formed ±328 mM CB-polyP by
polymerizing fibrinogen (2.65  mM, with 9% labeled with DL550-
fibrinogen) as above.
Statistical analysis
Statistical analysis was performed in GraphPad Prism® 5.04
using one-way analysis of variance or two-way analysis of vari-
ance with Bonferroni post hoc test or an unpaired Student’s t-test (2-
tailed). P<0.05 was considered to be significant.  
Results
PolyP promotes uPA-mediated plasmin generation
Our work has previously established that polyP inter-
feres with the plasminogen activator function of tPA4
while augmenting plasminogen activation by FXIIa.14 Here
we address the role of polyP on uPA-mediated plasmino-
gen activation using the fluorogenic substrate D–VLK-
AMC. PolyP dramatically enhanced the rate of plasmin
generation (3.96±0.34 vs. 0.84±0.08 pM/s; P<0.001) during
uPA-mediated fibrinolysis (Figure 1A). In contrast, and
consistent with our previous results4, a decrease in the
rate (0.74±0.06 vs. 1.17±0.14 pM/s in P<0.05) and amount
of plasmin generation was observed during tPA-mediated
fibrinolysis (Figure 1B). The ability of polyP to enhance
the rate of uPA-mediated lysis was dose-dependent up to
32.8 mM after which it decreased before increasing again
at 164 mM (Figure 1C). Above this concentration the rate
of plasmin generation was greatly enhanced with a 6-fold
increase at 328 mM polyP. In marked contrast, downregu-
lation of tPA-mediated plasmin generation required con-
centrations of greater than 70 mM and was not strongly
does-dependent (Figure 1D).
Plasminogen concentration attenuates the cofactor
function of polyP in uPA-mediated plasmin generation
We next analysed the impact of plasminogen concentra-
tion on the cofactor function of polyP. Plasmin generation
was monitored during clot lysis at various concentrations
of plasminogen. The rate of plasmin generation by uPA
and tPA in clots was directly proportional to the Glu-plas-
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minogen concentration (Figure 2A-B). The presence of
polyP significantly increased the rate of uPA-mediated
plasmin generation by around 75–82% at all Glu-plas-
minogen concentrations (Figure 2A). In marked contrast,
polyP attenuated tPA-mediated plasmin generation at all
Glu-plasminogen concentrations, with a maximal reduc-
tion at 1 mM Glu-plasminogen (Figure 2B). Cleavage of the
activation peptide of Glu-plasminogen by plasmin forms
an intermediate form, Lys-plasminogen, which displays
increased affinity for fibrin15 and is more readily cleaved
by plasminogen activators.7,16,17 Overall plasmin genera-
tion by uPA occurs at a significantly faster rate in clots
formed with Lys-plasminogen compared to Glu-plasmino-
gen and is directly proportional to the concentration
(Figure 2C-D). Interestingly, Lys-plasminogen overcame
the cofactor function of polyP on uPA-mediated plasmin
generation, significantly decreasing the magnitude of the
effect from 79% at 0.125 mM Lys-plasminogen to 9% at 
1 mM Lys-plasminogen (Figure 2C).  With tPA there was a
similar attenuation of plasmin generation (approximately
37%) at all Lys-plasminogen concentrations analysed
(Figure 2B, D).  
polyP binds with a higher affinity to uPA than tPA
We have previously demonstrated that polyP binds to
Glu-plasminogen.14 Here we use biotin-labelled polyP in a
plate-based assay to determine the binding affinity to (A)
uPA and (B) tPA. polyP bound with approximately 25-fold
higher affinity to uPA (Kd=9.8 nM) than tPA (Kd=245.3 nM;
Figure 3). Interestingly, binding of polyP did not alter the
activity of uPA and no specific binding of polyP to plasmin
was detected (data not shown). We have shown that polyP
stimulates autoactivation of FXII to an active single chain
FXII (scFXIIa)18 and enhances the plasminogen activator
capacity of FXIIa.14 We found that the high affinity inter-
action of uPA and polyP was similar to the interaction of
polyP with FXII (Kd=7.9 nM) and FXIIa (Kd=4.0 nM)
(Online Supplementary Figure S1).
polyP enhances uPA-mediated lysis in a concentration
and polymer length dependent manner
Incorporation of polyP during clot formation shortened
the uPA-mediated 50% clot lysis time by 43.7±1.7 min
(P<0.0001; Figure 4A). In contrast, tPA-mediated clot lysis
was delayed on inclusion of polyP (Figure 4B), as previous-
ly reported.4 The cofactor function of polyP on uPA-medi-
ated lysis was concentration dependent and required 
66 mM or higher to significantly stimulate the rate of lysis
(Figure 4C). The use of polyP of more refined chain length
revealed that polymers of >14-mer were required to pro-
mote uPA-mediated lysis (Figure 4D).  
Plasminogen modulates polyP-mediated effects 
on fibrinolysis
The mode of action of tPA and uPA differ significantly,
with tPA relying on the interaction with fibrin for efficient
plasminogen activation, while uPA is fibrin independent.
We investigated the relationship between plasminogen
and polyP-mediated effects on fibrinolysis. A clear con-
centration dependence was observed with Glu-plasmino-
gen on uPA-mediated lysis, with maximal lysis at 0.75 mM
plasminogen (Figure 5A). The impact of Glu-plasminogen
on tPA-mediated lysis was less pronounced, but a small
effect was observed with maximal lysis at 0.5 mM plas-
minogen (P<0.01; Figure 5B). polyP significantly accelerat-
ed uPA-mediated lysis at all Glu-plasminogen concentra-
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Figure 1. PolyP stimulates uPA-mediated plasmin generation in a concentration dependent manner. Fibrin clots were prepared containing 2.4 mM fibrinogen, 0.24
mM Glu-plasminogen, 20 pM tPA or 180 pM uPA ± 328 mM (polyP65). Clotting was initiated with thrombin (0.25 U/mL) and CaCl2 (5 mM) and plasmin generation was
quantified by incorporating the fluorogenic substrate D–VLK-AMC and monitoring fluorescence release (FU; Ex 360 nm Em 460 nm). (A) uPA and (B) tPA mediated
plasmin generation curves. Rate of plasmin generation in clots formed with varying polyP concentration (0-1.3 mM polyP65) for (C) uPA and (D) tPA. Data are expressed
as mean ± standard error of the mean, n≥ 3. PolyP:  polyphosphate; tPA: tissue plasminogen activator; uPA: urokinase plasminogen activator; FU: fluorescence units,
Ex: excitation; EM: emission.
tions tested, however, the cofactor function of polyP was
tempered at high concentrations. Inclusion of polyP
delayed tPA-mediated lysis at all Glu-plasminogen con-
centrations tested by an average of 40%; therefore,
increasing the Glu-plasminogen concentration did not
alter the efficacy of polyP on tPA-driven lysis.  
Clots containing Lys-plasminogen lyse significantly
faster than those containing Glu-plasminogen (Figure 5C-
D). A dose-dependent relationship exists between 
Lys-plasminogen concentration and uPA-mediated lysis,
with 50 % lysis times decreasing from 51.1±1.36 min at
0.125 mM to 17.2±0.32 min at 1 mM (Figure 5C). In con-
trast, there is no relationship between Lys-plasminogen
concentration and tPA-mediated lysis, exemplifying the
different modes of action of these plasminogen activators
(Figure 5D). Similar to the results with plasmin generation,
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Figure 2. High concentrations of plasminogen attenuate the cofactor function of polyP in uPA-mediated plasminogen activation. Fibrin clots were prepared with
2.4 mM fibrinogen, 0 -1 mM (A-B) Glu-plasminogen or (C-D) Lys-plasminogen, (A, C) 180 pM uPA or (B, D) 20 pM tPA ± 328 mM polyP65. Clotting was initiated with
thrombin (0.25 U/mL) and CaCl2 (5 mM).  Plasmin generation in clots was quantified by incorporating the fluorogenic substrate D–VLK-AMC and monitoring fluores-
cence release (FU; Ex 360 nm Em 460 nm). *P<0.05; **P<0.01, ***P<0.001 and ****P<0.0001 compared with control clots. Data are expressed as mean ±
standard error of the mean, n≥3. polyP: polyphosphate; tPA: tissue plasminogen activator; uPA: urokinase plasminogen activator; FU: fluorescence units; Ex: excita-
tion; EM: emission.
Figure 3. polyP binds to uPA with a significantly higher affinity than tPA. Binding of uPA or tPA (0–400 nM) to biotin-labelled polyP (71 mM) bound to streptavidin
coated stripwells. Bound uPA (orange) or tPA (blue) was detected with chromogenic substrates (S2288 or CS-61 44 respectively) by reading the change in
absorbance at 405 nm every 30 seconds (s) for 200 minutes (min). No unspecific binding was detected in the absence of biotin-labelled polyP (black lines). Data
are expressed as baseline corrected nonlinear fit as mean ± standard error of the mean (SEM), n=4. PolyP:  polyphosphate; tPA: tissue plasminogen activator; uPA:
urokinase plasminogen activator.
  A                                                                                B
  C                                                                                D
  A                                                                       B
the cofactor function of polyP on uPA-mediated lysis is
lost at high Lys-plasminogen concentrations (Figure 5C).
Whereas, polyP delayed tPA-mediated lysis by approxi-
mately 20 % at all Lys-plasminogen concentrations (Figure
5B, D).   
polyP localization during fibrinolysis 
polyP is found to co-localize with fibrinogen, as previ-
ously reported,19 and plasminogen in fibrin clots. During
fibrinolysis polyP concentrates within the fibrin dense
knots of the clot alongside plasminogen and fibrinogen
(Figure 6A). Colocalization was observed with both uPA
and tPA but only the data for uPA is shown. Lysis was ini-
tiated at the edge of the clot, by addition of plasminogen
activator, and as it progressed through the fibrin network
polyP and plasminogen were found to remain colocalized
within the lysis front (Figure 6B).
Visualization of the cofactor function of polyP during
uPA-mediated lysis in real-time
Fluorescent confocal microscopy was used to visualize
lysis in real-time following application of either uPA or
tPA to the edge of fibrin clots. The rate of fibrinolysis in
the control clot was similar in the presence of uPA or tPA
(Figure 7A-B). As uPA-mediated lysis progresses
plasmin(ogen) is dispersed throughout the clot, with a
small concentrated zone at the leading edge (Figure 7A), in
contrast plasminogen is restricted to a distinct zone at the
leading edge in tPA-mediated lysis (Figure 7B). The incor-
poration of polyP significantly accelerates uPA-mediated
lysis (Figure 7A) with full lysis observed on average at 6
min (Online Supplementary Video S1B) compared to greater
than 9 min in the control (Online Supplementary Video S1A). 
Discussion
Over the last decade a role for the biomolecule polyP in
the regulation of hemostasis has been exposed. The ability
of polyP to modulate fibrinolysis manifests on several 
levels. We and others4,20 have demonstrated altered fibrin
structure in the presence of polyP, a consequence of which
is tempered binding of tPA and plasminogen to fibrin and
subsequent down-regulation of fibrinolysis.4 In contrast,
in this study we show that that polyP significantly 
accelerates uPA-mediated plasminogen activation thereby
augmenting fibrinolysis. The rate of plasmin formation
was approximately 5-fold faster in the presence of polyP
and was dependent on concentration and polymer length,
with polymers of 60-mer or greater required to accelerate
lysis. We determined that polyP binds with a 25-fold high-
er affinity to uPA than tPA and potentially accelerates con-
version of Glu-plasminogen to the intermediate form Lys-
plasminogen via a template mediated effect. Importantly,
for the first time we visualize polyP during real-time lysis
of fibrin clots and find it to be localized within fibrin
dense areas alongside plasminogen, consistent with its
known binding to these proteins.4,14,19
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Figure 4. polyP acts as a cofactor to accelerate uPA-mediated fibrinolysis in a concentration and polymer size dependent manner. Fibrin clots were prepared con-
taining 2.4 mM fibrinogen, 0.24 mM Glu-plasminogen, 20 pM tPA or 180 pM uPA ±328 mM polyP65. Clotting was initiated with thrombin (0.25 U/mL) and CaCl2 (5 mM)
and fibrinolysis monitored at 340 nm shown as percentage turbidity over time with (A) uPA or (B) tPA. (C) uPA-mediated fibrinolysis with 0-1.3 mM polyP65 or (D) polyP
of various chain lengths at equivalent concentration of monomer (328 mm). *P<0.05, ***P<0.001 and ****P<0.0001 compared with control clots. Data are
expressed as mean 50 % lysis time (t1/2) ± standard error of the mean, n≥3. polyP: polyphosphate; tPA: tissue plasminogen activator; uPA: urokinase plasminogen
activator.
  A                                                                                B
  C                                                                                D
Despite their homology in structure, the mechanism of
tPA and uPA-mediated plasminogen activation are very
different. Efficient plasminogen activation by tPA requires
its association with the fibrin surface, that is fibrin orches-
trates its own destruction by plasmin. Binding of tPA to
fibrin is largely attributed to its finger domain,21,22 while
plasminogen associates with fibrin via kringle domains.23
The colocalization of enzyme and substrate on fibrin, as a
surface, is crucial, as tPA is a poor plasminogen activator
in solution. Circulating fibrinogen cannot accelerate plas-
minogen activation by tPA, as the sites are only exposed
in fibrin24 thereby localizing plasmin formation to the fi-
brin clot. In marked contrast uPA does not bind fibrin and
is reasonably efficient at activating plasminogen in solu-
tion. However, its cellular receptor, uPAR, localizes uPA
via its amino terminal fragment to the cell surface, thereby
augmenting plasminogen activation due to an increase in
local reactant concentration. 
The high affinity interaction of uPA and plasminogen14
with polyP and dependence on substrate and template
concentration are indicative of a template mechanism of
activation.  In line with this polyP polymers of around 60-
mer were required to stimulate plasminogen activation by
uPA, suggesting this length is critical to accommodate
binding of both enzyme and substrate to the same tem-
plate. Indeed, a template effect of polyP in thrombin-
mediated activation of FV to FVa has previously been
reported.25 Polymers of around 80-100-mer are secreted
following platelet stimulation2 with insoluble divalent
cation bound polyP nanoparticles remaining associated
with the activated platelet membrane.26 Platelet-derived
polyP could actively participate in these template-media-
ted reactions within the milieu of a thrombus where local
concentrations of the polymer will be high. 
Previously an inhibitory effect of polyP on uPA-media-
ted fibrinolysis was described in a plasma based system.25
The data presented here delineates the role of polyP
specifically on plasminogen activation by uPA using a
purified system. The roles of polyP in hemostasis are mul-
tifaceted and coagulation and fibrinolysis are inextricably
linked. It is therefore difficult, at this current time, to
exclude the fact that these differences cannot be attributed
to different experimental setups, reagents and indeed an
impact of polyP on a different part of the pathway.  
Intriguingly, the cofactor function of polyP described
here in uPA-mediated plasminogen activation is markedly
more pronounced than in uPA-mediated fibrinolysis. This
can potentially be explained by an increase in the number
of binding sites, that is plasminogen has the capacity to
bind both polyP and lysine residues exposed on partially
degraded fibrin generated following onset of lysis.23 Thus,
the increase in surface binding sites on fibrin for plasmino-
gen tempers the cofactor function of polyP. Therefore,
there is a more evident effect at low plasminogen concen-
trations, where fewer lysine residues will be generated.
Given the anionic nature of polyP it is feasible that it asso-
ciates with positively charged lysine residues on fibrin,
thereby obscuring the kringle-dependent binding of plas-
minogen to fibrin, however, high plasminogen concentra-
tions eliminate the need for fibrin binding.  
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haematologica | 2021; 106(2) 527
Figure 5. The cofactor function of polyP in uPA-mediated fibrinolysis is modulated by plasminogen concentration and form. Fibrin clots were prepared containing
2.4 mM fibrinogen, 0-1 mM (A-B) Glu-plasminogen or (C-D) Lys-plasminogen, (A, C) 180 pM uPA or (B, D) 20 pM tPA ±328 mM polyP65. Clotting was initiated with throm-
bin (0.25 U/mL) and CaCl2 (5 mM) and fibrinolysis monitored at 340 nm. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 compared with control clots. Data
are expressed as mean ± standard error of the mean, n≥3. polyP: polyphosphate; tPA: tissue plasminogen activator; uPA: urokinase plasminogen activator.
  A                                                                                B
  C                                                                                D
Our recent study19 investigating the molecular mecha-
nisms underpinning the changes in fibrin structure in the
presence of platelet-derived polyP revealed a significant
change in fibrin polymerisation which stunts protofibril
growth; thus providing an explanation for the characteris-
tic ‘knotted’ appearance.4 Downstream this impacts on
the mechanical properties of a clot, reducing overall stiff-
ness and increasing its ability to deform plastically.19 Here,
we find that polyP is localized within these ‘knotted’
regions of fibrin alongside plasminogen. Analysis of lysis
in real-time reveals significant acceleration of uPA-media-
ted fibrinolysis presumably due to the direct colocaliza-
tion of cofactor, enzyme and substrate. Previous work has
shown that co-assembly of uPA and plasminogen on the
same surface is not a prerequisite to stimulate plasmin for-
mation.27 This crosstalk mechanism permits localization
of plasminogen and uPA on different cellular surfaces or
binding of plasminogen to fibrin while uPA is associated
with cellular uPAR. A similar mechanism could explain
our current observations; that is uPA is localized on polyP
while plasminogen is bound to either polyP or partially
degraded fibrin. Future work is necessary to ascertain the
effect polyP may have on plasminogen activation on the
surface of monocytes and neutrophils, which express both
uPA and its cellular receptor uPAR. 
Plasminogen circulates in the native or Glu-plasminogen
form but can be cleaved by plasmin at Lys77-Lys78 to gener-
ate Lys-plasminogen. This cleavage prompts changes in
the properties of the zymogen thereby providing a posi-
tive feedback mechanism.28 Lys-plasminogen is a conside-
rably better substrate for both tPA29 and uPA30 and displays
enhanced affinity for fibrin.31,32 Surface-bound Glu-plas-
minogen is more readily cleaved to Lys- plasminogen than
in solution.33 We have previously shown,14 and confirmed
in this study, that plasminogen, but not plasmin, bindsdi-
rectly to polyP, as does the activator uPA. Co-assembly of
Glu-plasminogen and uPA on the polyP surface will aug-
ment local concentrations of the reactants. An initial spark
of plasmin formation will drive cleavage of Glu-plasmino-
gen to Lys-plasminogen. Once formed Lys-plasminogen is
more readily activated to plasmin than native Glu-plas-
minogen. Stimulation of uPA-mediated plasminogen acti-
vation by polyP is diminished when Lys-plasminogen is
used, indicating that its cofactor function may lie in initial
surface-mediated conversion of Glu- to Lys-plasminogen,
ultimately accelerating plasmin formation. We have
shown that plasmin does not bind to polyP4 or impact on
its enzymatic activity indicating that the enhanced lysis
arises at the level of plasminogen activation.
The lysine analogue, tranexamic acid (TXA), downregu-
lates lysis by blocking tPA-mediated plasmin generation.
The effect of TXA on uPA-mediated plasmin generation is
more complex, with high concentrations of TXA augment-
ing plasmin generation, despite this fibrinolysis is still inhib-
ited. Enhanced activation of plasminogen by uPA in the
presence of TXA is indicative of a conformational change in
plasminogen, from a closed structure to an open and more
readily activated form.34 Our observations with polyP are
similar, in that binding of Glu-plasminogen appears to aug-
ment its susceptibility to uPA-mediated cleavage indicative
of a conformational change in the protein.  
The fibrin specificity of tPA has led to the view that it is
the dominant plasminogen activator in hemostasis,
whereas, uPA has been implicated in plasmin-mediated
cell migration, tissue remodelling and activation of latent
growth factors and cytokines.35 TPA has been implicated
in the degradation of deep vein thrombi in humans36 but
genetic deficiency in mice has no impact. In marked con-
trast, uPA deficiency in mice markedly impairs venous
thrombus resolution37 and conversely delivery of uPA to
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Figure 6. polyP colocalizes with fibrinogen and plasminogen during fibrinolysis.  Fibrin clots were formed containing fibrinogen (2.65 mM, 9% DyLight 550-labeled),
Glu-plasminogen (1.25 mM, 20% DyLight 633-labeled) 328 mM Cascade-blue labeled polyP70 (CB-polyP), thrombin (0.25 U/mL), CaCl2 (5 mM). (A) polyP and plas-
minogen largely accumulate in the knotted regions of fibrin. (B) Fibrinolysis was initiated by exogenous uPA (75 nM). Plasminogen and polyP strongly colocalize at
the lysis front during clot lysis, as indicated by the arrows. Scale bars =10 mm. polyP: polyphosphate; uPA; urokinase plasminogen activator.
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thrombi, either directly38 or via uPA expressing mono-
cytes,39 improves thrombus dissolution. Cross-talk
between neutrophils, monocytes and platelets contributes
to deep vein thrombosis40 and it is feasible that platelet-
derived polyP could augment monocyte-derived uPA-
mediated plasmin formation and facilitate thrombus reso-
lution.  
Platelets contain approximately 0.74 nmol/108 platelets1
therefore concentrations in whole blood are estimated to
reach around ≈3 mM following platelet activation.25
However, in platelet dense regions of thrombi concentra-
tions could far exceed this; particularly as we and others
have also shown that polyP remains bound to the activa-
ted platelet membrane.26,41 Elegant studies have revealed
that solute transport within the core regions of thrombi is
restricted42-44 and as such the diffusion rate of platelet-
derived polyP within this milieu will be restricted. PolyP
nanoparticles formed on the activated platelet membrane
trigger contact activation26 and our laboratory has
described a role for polyP in augmenting FXIIa-mediated
plasminogen activation, with the platelet surface acting as
a focal point for colocalization.14 By acting as a template
for plasminogen activation by FXIIa or uPA, platelet-asso-
ciated polyP nanoparticles could, under certain conditions,
function to limit thrombus size.
Here we show that polyP binds to uPA with a high
affinity and enhances uPA-mediated plasmin generation
thereby augmenting the rate of fibrinolysis. This is in
sharp contrast to the inhibitory effect of this polyanion
on tPA-mediated plasminogen activation.4 The strong
binding of uPA and plasminogen is suggestive of a tem-
plate mechanism that results in enhanced conversion of
Glu-plasminogen to Lys-plasminogen and is supported
by the colocalization of the reactants on fibrin. The inter-
action of Glu-plasminogen with polyP may additionally
result in a conformational change thereby facilitating its
activation by uPA. Our data define a novel cofactor func-
tion of polyP in regulation of plasminogen activation by
uPA that drives fibrinolysis in real time and may have
important implications for physiological processes such
as thrombus resolution, cell migration and tissue remod-
eling.
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Figure 7. Real-time lysis of fibrin clots reveals the cofactor function of polyP on uPA-mediated fib-
rinolysis. Fibrinolysis by exogenous PA (75 nM) was monitored by fluorescent confocal microscopy
of clots formed from fibrinogen (2.65 mM, 9% DyLight 488-labeled), plasminogen (1.25 mM, 20%
DyLight 633-labelled), thrombin (0.25 U/mL), CaCl2 (5 mM) ± 328 mM polyP65. Images were taken
every 15 seconds (s). (A) uPA and (B) tPA mediated fibrinolysis over time showing fibrinogen (green),
plasminogen (red) and merged images where co-localisation is visualised as yellow. Representative
image from n=3, scale bar=10 mm. (C) Quantification of lysis time in s as determined by the time
taken to lyse scan area (134.8 mm x 134.8 mm). Data expressed as mean ±standard error of the
mean, n=3. polyA: polyphosphate; tPA: tissue plasminogen activator; uPA: urokinase plasminogen
activator.
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